Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C14H17FN2O3 |
| Molecular Weight | 280.2948 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@@H]1N(C(=O)OC(C)C)C2=C(NC1=O)C=CC(F)=C2
InChI
InChIKey=KELNNWMENBUHNS-NSHDSACASA-N
InChI=1S/C14H17FN2O3/c1-4-11-13(18)16-10-6-5-9(15)7-12(10)17(11)14(19)20-8(2)3/h5-8,11H,4H2,1-3H3,(H,16,18)/t11-/m0/s1
Opaviraline (also known as GW 420867), a nonnucleoside reverse transcriptase inhibitor that was studied for the treatment of HIV infections. The drug participated in clinical trials phase II in Germany, in South Africa, and in the United Kingdom, however, these studies were discontinued.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors. | 2000 Apr 10 |
|
| Mutational analysis of trp-229 of human immunodeficiency virus type 1 reverse transcriptase (RT) identifies this amino acid residue as a prime target for the rational design of new non-nucleoside RT inhibitors. | 2000 May |
|
| The N137 and P140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase are instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugs. | 2005 Apr 25 |
|
| Discovery of TSAO derivatives with an unusual HIV-1 activity/resistance profile. | 2006 Aug |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C97453
Created by
admin on Fri Dec 15 16:30:38 GMT 2023 , Edited by admin on Fri Dec 15 16:30:38 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DB07884
Created by
admin on Fri Dec 15 16:30:38 GMT 2023 , Edited by admin on Fri Dec 15 16:30:38 GMT 2023
|
PRIMARY | |||
|
Q3A8EU2NMU
Created by
admin on Fri Dec 15 16:30:38 GMT 2023 , Edited by admin on Fri Dec 15 16:30:38 GMT 2023
|
PRIMARY | |||
|
C90786
Created by
admin on Fri Dec 15 16:30:38 GMT 2023 , Edited by admin on Fri Dec 15 16:30:38 GMT 2023
|
PRIMARY | |||
|
154048
Created by
admin on Fri Dec 15 16:30:38 GMT 2023 , Edited by admin on Fri Dec 15 16:30:38 GMT 2023
|
PRIMARY | |||
|
300000034254
Created by
admin on Fri Dec 15 16:30:38 GMT 2023 , Edited by admin on Fri Dec 15 16:30:38 GMT 2023
|
PRIMARY | |||
|
CHEMBL301370
Created by
admin on Fri Dec 15 16:30:38 GMT 2023 , Edited by admin on Fri Dec 15 16:30:38 GMT 2023
|
PRIMARY | |||
|
178040-94-3
Created by
admin on Fri Dec 15 16:30:38 GMT 2023 , Edited by admin on Fri Dec 15 16:30:38 GMT 2023
|
PRIMARY | |||
|
DTXSID60170415
Created by
admin on Fri Dec 15 16:30:38 GMT 2023 , Edited by admin on Fri Dec 15 16:30:38 GMT 2023
|
PRIMARY | |||
|
8020
Created by
admin on Fri Dec 15 16:30:38 GMT 2023 , Edited by admin on Fri Dec 15 16:30:38 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
